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Abstract
Background: PET/CT has recently been shown to be a viable alternative to traditional post-infusion imaging methods
providing good quality images of 90Y-laden microspheres after selective internal radiation therapy (SIRT). In the present
paper, first we assessed the quantitative accuracy of 90Y-PET using an anthropomorphic phantom provided with lungs,
liver, spine, and a cylindrical homemade lesion located into the hepatic compartment. Then, we explored the accuracy
of different computational approaches on dose calculation, including (I) direct Monte Carlo radiation transport using
Raydose, (II) Kernel convolution using Philips Stratos, (III) local deposition algorithm, (IV) Monte Carlo technique (MCNP)
considering a uniform activity distribution, and (V) MIRD (Medical Internal Radiation Dose) analytical approach. Finally,
calculated absorbed doses were compared with those obtained performing measurements with LiF:Mg,Cu,P TLD chips
in a liquid environment.
Results: Our results indicate that despite 90Y-PET being likely to provide high-resolution images, the 90Y low branch
ratio, along with other image-degrading factors, may produce non-uniform activity maps, even in the presence of
uniform activity. A systematic underestimation of the recovered activity, both for the tumor insert and for the liver
background, was found. This is particularly true if no partial volume correction is applied through recovery coefficients.
All dose algorithms performed well, the worst case scenario providing an agreement between absorbed dose
evaluations within 20%. Average absorbed doses determined with the local deposition method are in excellent
agreement with those obtained using the MIRD and the kernel-convolution dose calculation approach.
Finally, absorbed dose assessed with MC codes are in good agreement with those obtained using TLD in liquid
solution, thus confirming the soundness of both calculation approaches. This is especially true for Raydose, which
provided an absorbed dose value within 3% of the measured dose, well within the stated uncertainties.
Conclusions: Patient-specific dosimetry is possible even in a scenario with low true coincidences and high random
fraction, as in 90Y–PET imaging, granted that accurate absolute PET calibration is performed and acquisition times are
sufficiently long. Despite Monte Carlo calculations seeming to outperform all dose estimation algorithms, our data
provide a strong argument for encouraging the use of the local deposition algorithm for routine 90Y dosimetry based
on PET/CT imaging, due to its simplicity of implementation.
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Background
Radioembolization with 90Y, or selective internal radiation
therapy (SIRT), is a catheter-based therapy with the poten-
tial of delivering a high-radiation dose directly to liver
tumors or metastases meanwhile minimizing the effects on
healthy liver parenchyma [1–6]. The radiopharmaceutical
consists of non-biodegradable 90Y-imprinted resin or glass-
based microspheres with a diameter of approximately 20–
40 μm. The tumoricidal effect is produced by beta particles
emitted from 90Y incorporated on the surface of the resin
matrix or integrally bound within the microsphere matrix,
in the case of glass beads. The selectivity of SIRT is based
on anatomic and physiological aspects of liver tumors and
metastases that can be exploited for the selective delivery
of the microspheres [7–9]. Microspheres are injected into
the hepatic artery and delivered directly into the smaller
blood vessels that feed the tumor, therefore being trapped
within the tumor microvasculature.
It is worth noticing that in recent years, radioactive
166Ho poly(L-lactic acid) microspheres (166Ho-PLLA-MS)
have been developed as a viable alternative to liver radio-
embolization with 90Y microspheres. In addition to high-
energy beta-radiation, 166Ho emits gamma radiation that
allows gamma camera quantitative imaging and dosimetry
[10, 11]. Furthermore, holmium is highly paramagnetic
and can be visualized using traditional magnetic resonance
imaging (MRI), thereby allowing for MRI-based absorbed
dose calculations [11–13].
90Y is a pure β-emitting radionuclide with maximum and
average energies of 2.28 MeV and 933.7 keV, respectively.
The corresponding maximum and average path lengths of
the emitted β particles in soft tissue (1 g/cm3) are 11 and
2.5 mm. Although 90Y has been traditionally considered as
a pure β− emitter, the decay of this radionuclide has a
minor branch to the 0+ first excited state of 90Zr at
1.76 MeV that is followed by a β+/β− emission. This internal
pair production has been largely studied in the past because
it is generated by a rare electric monopole transition (E0)
between the states 0+/0+ of 90Zr. A thorough explanation of
the emission of β+ particles via internal pair production in
the 0+–0+ transition of 90Zr is provided elsewhere [14].
In the last years, the small positronic emission has
been exploited for 90Y–PET imaging studies after liver
radioembolization, with the aim to provide quantitative
post-treatment imaging and to prospectively improve
the therapy [15–27]. Furthermore, the possibility of
detecting β+ emissions from 90Y by PET scanners is paving
the way for an accurate patient-specific dosimetry. Because
microspheres can be assumed to be a permanent implant,
the use of appropriate dose calculation algorithms allows
quantitative 90Y–PET images to be converted into absorbed
dose maps. The accuracy of dose calculation is of para-
mount importance in liver radioembolization as side effects
and treatment outcome are related to absorbed doses. Over
the last few years, there has been an intensifying debate
revolving around the most accurate dosimetric approach
for the assessment of the absorbed dose in molecular radio-
therapy. Many authors obtained absorbed dose maps from
90Y–PET data performing three-dimensional convolution
of the kernel function with the cumulated activity. A
recent analysis by Pasciak et al. [26] proposed the use of
local deposition technique, while previous studies used
the analytical MIRD (Medical Internal Radiation Dose)
approach.
The aim of this study is to investigate the impact of differ-
ent computational approaches on absorbed dose calculation,
starting from the quantitative accuracy of 90Y–PET. The
workflow followed in the present work was structured into
three logically sequential steps, which are detailed below.
(1) Firstly, the quantitative accuracy of reconstructed
90Y–PET data was evaluated using a cylindrical phantom
and an IEC (International Electrotechnical Commission)
body phantom for the assessment of recovery coefficients.
Then, the PET camera’s ability to produce 90Y quantitative
data was validated using an anthropomorphic phantom
with a liver cavity and a background compartment. A
hollow cylindrical insert was fixed into the liver cavity of
the anthropomorphic phantom with the intent to simulate
a hepatic lesion. Acquisitions were performed using a
General Electric (GE) Discovery ST PET/CT scanner with
a 6:1 tumor to background activity concentration ratio.
The anthropomorphic phantom was acquired at days 1, 4,
5, 6, and 12 post-phantom preparation down to an activity
concentration of 0.31 ± 0.02 MBq mL−1 for the lesion
insert (initial activity concentration 5.5 ± 0.3 MBq mL−1)
and 50 ± 3 kBq mL−1 for the liver background (initial
activity concentration 0.89 ± 0.04 MBq mL−1). In the
present phantom study, activity measurements were per-
formed using a well-type radionuclide calibrator available
on site and traceable to the Italian National Institute of
Ionizing Radiation Metrology for the geometry being mea-
sured (accuracy within ± 5% at k = 2 level, as recommended
by AAPM report 181 [28]). PET images were reconstructed
using the standard GE algorithm (full 3D-OSEM VUEPoint
HD two iterations, 15 subsets) and corrected for attenu-
ation, scatter, random, and dead time using manufacturer
software. Random and scatter corrections are incorporated
into the iterative algorithm, with scatter correction per-
formed using a fully 3D approach that considers both
the axial and trans-axial scatter components.
(2) The second part of the study was devoted to absorbed
dose calculations. Absorbed doses to the cylindrical insert
were calculated from 90Y–PET images obtained in the
previous stage, benchmarking different computational
algorithms including (I) full Monte Carlo (MC) using
Raydose [29]; (II) Kernel convolution using Philips Stratos
[30]; (III) local deposition [26]; (IV) MC N-Particle code
[31] (MCNP4c); and (V) MIRD analytical approach [32].
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(3) Ultimately, absorbed doses calculated using MC codes
were compared with those obtained performing experi-
mental measurements with high-sensitivity LiF:Mg,Cu,P
thermoluminescent dosimeters (TLDs) inside the same
cylindrical insert filled with a homogenous 90YCl3 solution.
LiF:Mg,Cu,P chips were fully characterized in terms of
absorbed dose to water at the Italian National Institute of
Ionizing Radiation Metrology (ENEA-INMRI) using the
available 60Co reference gamma beam [33]. In the present
study, the average absorbed dose to water obtained from
TLD measurements was considered the gold standard.
The observation reported here provides key insight into
dosimetry calculations related with 90Y–PET data. To the
best of the authors’ knowledge, there are no published
literature studies aimed to compare measured absorbed
dose with dose values obtained from 90Y–PET quantitative
data.
The results reported in the present paper are organized
into three separate sections, reflecting the abovementioned
workflow.
Results
Quantitative analysis
A cylindrical phantom, an IEC body phantom, and an
anthropomorphic phantom were used to assess and
validate the PET camera’s ability to image 90Y and produce
quantitative data. 90Y-chloride in an aqueous solution of
0.1 mol dm−3 hydrochloric acid was used for phantom
experiments as microspheres tend to settle over time
during imaging, resulting in a non-uniform distribution
of 90Y.
Adsorption of 90YCl3 on the inner walls of plastic
phantoms may negatively affect PET quantitative imaging
studies [34]. Therefore, in the present study, phantom prep-
aration was performed using ultrapure water (18 MΩ cm)
and adding diethylenetriaminepentaacetic acid (DTPA)
at a concentration of 100 μg g−1 to the stock solution to
prevent binding of 90Y to phantom polymethylmethacrylate
(PMMA) walls. Activity was dispensed into the phantoms
by accurate volume measurements performed using a
calibrated four significant digit balance. Double weighing
of the volume to be dispensed was performed for each
phantom.
The 90Y calibration factor on our GE Discovery DST
PET/CT scanner was evaluated rescaling the 18F calibra-
tion factor by the 90Y beta plus branch ratio (0.00318%).
This procedure was validated performing an overnight
acquisition of a cylindrical phantom (5640 mL volume,
Fig. 1a) uniformly filled with (1.53 ± 0.08) GBq of 90YCl3
mixed with pure water (273 ± 14 kBq mL−1). The phan-
tom was positioned at the center of the field of view
(FOV) and a 16-h single bed acquisition was launched.
After the acquisition, data were reconstructed using two
iterations, 15 subsets. Past research on the same Discovery
ST PET/CT scanner [16] showed that two iterations rep-
resent a good trade-off between signal recovery and image
noise on object with volume larger than 10 mL, approxi-
mately. Images were elaborated with the built-in PET
VCAR GE software. The recovered concentration in the
uniform phantom was 257 ± 16 kBq mL−1 (6.2% standard
deviation) with an underestimation of − 5.9% with respect
to the true concentration (Table 1). This finding confirms
the validity of the proposed calibration procedure as the
Fig. 1 Quantitative accuracy of 90Y–PET acquisitions. a Cylindrical phantom used for validating PET calibration uniformly filled with an activity
concentration of 90YCl3 at a concentration of 273 ± 14 kBq mL
−1 at the time of acquisition. Diethylenetriaminepentaacetic acid (DTPA) at a
concentration of 100 μg g−1 was used to prevent binding of 90Y to the phantom PMMA walls. An overnight (16 h) single bed acquisition was
performed. b Transversal slice of the NEMA IEC/2001 phantom used for the assessment of recovery coefficients needed for partial volume corrections.
RCs are defined as the ratio of the measured activity concentration to true activity concentration. The phantom is provided with six fillable spheres of
varying volume (0.52, 1.15, 2.57, 5.57, 11.49, and 26.52 mL), each filled with an activity concentration of 2.28 ± 0.11 MBq mL−1 at the time of acquisition.
Sagittal (c) and coronal (d) view of the same phantom are also shown. e Recovery coefficients as a function of the volume of the sphere. RCs lie in the
range 0.2–0.86 for the smallest sphere and largest sphere, respectively. The relative uncertainty was estimated to be 5% of the RC value, corresponding
to the relative uncertainty associated with the activity as measured by the clinical radionuclide calibrator
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true and the measured activity concentrations agree well
within the stated uncertainties.
Partial volume effect (PVE) was studied through the
assessment of absolute recovery coefficients (RCs) on
spherical objects, i.e., the ratio of the measured activity
concentration to true activity concentration. Regions of
interest (ROI) as large as the physical diameter of the
sphere were drawn. A NEMA IEC/2001 phantom with
six fillable spheres of varying volume (0.52, 1.15, 2.57,
5.57, 11.49, and 26.52 mL) was used for the assessment
of RCs (Fig. 1b–d). Each sphere was filled with a uniform
90YCl3 liquid solution having an activity concentration of
2.28 ± 0.11 MBq mL−1 at the time of acquisition. An 8:1
sphere-to-background ratio was used, as recommended by
the NEMA Standards Publication NU 2-2007 [35]. PVE
led to significant underestimation of the activity concen-
tration, especially in spheres with a volume below 10 mL,
approximately. RCs range from 0.2 for the smallest sphere
to 0.86, approximately, for the largest sphere (Fig. 1e).
The PET camera’s ability to produce 90Y quantitative
data was validated using an anthropomorphic phantom
with a liver cavity and a background compartment. A
homemade cylindrical PMMA insert was manufactured
and fixed into the liver cavity to simulate a hepatic
lesion. The nominal volume of the insert is 19.13 mL
(diameter 28.5 mm, height 30 mm). Measurements in
anthropomorphic geometry were performed using a 6:1
tumor to background activity concentration ratio, as this
uptake ratio is often encountered in the clinical practice.
The first scan was performed with an activity concentra-
tion of 5.5 ± 0.3 MBq mL−1 for the lesion insert and
0.89 ± 0.04 MBq mL−1 for the liver. The anthropo-
morphic phantom was then acquired at days 4, 5, 6, and
12 (according to the scanner availability) down to an
activity concentration of 0.31 ± 0.02 MBq mL−1 for the
lesion insert and 50 ± 3 kBq mL−1 for the liver. The
background compartment of the phantom was filled with
non-radioactive water. Activity distributions of 90Y–PET
images were analyzed in terms of differential activity
concentration volume histograms (dAVHs), generated
by binning the activity concentration values from each
voxel in the volume and calculating the volume of structure
containing an activity concentration given by bin:
dAVH ¼ − Δ
Δc
vi cið Þ
V
 
¼ − d
dc
v cð Þ
V
 
ð1Þ
where Δc is the binning resolution in terms of activity
concentration, vi is the i-th volume element containing
an activity concentration of at least ci, and V is the total
volume. dAVHs of the tumor insert are reported in Fig. 2,
while Fig. 3 shows the anthropomorphic phantom used
to perform 90Y–PET quantitative acquisitions. Despite
the cylindrical insert being uniformly filled with 90YCl3,
heterogeneous activity distributions were obtained from
90Y–PET data. As a general rule, visual inspection of the
images showed the presence of hot and cold spots in
regions of the phantom uniformly filled with 90Y (Fig. 2k–o).
From a quantitative point of view, positive-skewed dAVHs
were obtained for all acquisitions, i.e., activity concentration
values clustered more toward lower activity concentration
values with few higher values (Fig. 2a–j). This is in keeping
with previous research on noise in PET imaging, modeling
positive-skewed noise probability density function with
Poisson, negative binomial, log-normal, and gamma
distributions [36]. Consistently, we found that the lower
the number of detected β+ events (i.e., the noise level),
the higher the skewness value (Fig. 2a–j). A compre-
hensive study of noise in 90Y-PET imaging lies outside
the scope of the present study. The reader is referred to
Carlier et al. [37] for details.
A systematic underestimation of the recovered activity,
both for the tumor insert and for the liver background,
was found. This is particularly true if no partial volume
correction is applied through RCs. After the application
of RCs, differences with measured activity concentration
values reduce significantly with underestimations of the
order of 4% down to an activity concentration of about
2 MBq mL−1 (Table 2 and Fig. 4a). For lower activity
concentration values, deviations in the range 10–15%
were obtained down to 0.24 MBq mL−1 (Tables 2 and 3).
PVE typically occurs whenever the object size is less
than three times the full width at half maximum of the
reconstructed image resolution [38]. Therefore, PVE in
the liver were assumed negligible.
A homogeneity index, HIdAVH, was derived from dAVHs
to quantify the dispersion of the average activity within
the volume of interest (VOI) [39]:
HIdAVH ¼ 1Cmean
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃX vi
V
⋅ ci−Cmeanð Þ2
r
ð2Þ
where Cmean is the average activity concentration over
the selected VOI and ci the activity concentration at the
voxel level. For each acquisition, HIdAVH were plotted
as a function of the number of positrons emitted from
the VOI (Fig. 4b). Calculated HIdAVH are reported in
Table 1 Validation phantom. Recovered activity concentration in the uniform cylindrical phantom after an overnight acquisition
True activity concentration (MBq mL−1) Recovered activity concentration
in the uniform phantom (MBq mL−1)
Scan time (min) Reconstruction parameters Homogeneity index
0.273 ± 0.008 0.257 ± 0.016 960 2i, 15s 0.07
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Tables 1, 2, and 3. A power function of the form
y = axbwas used to fit data points, where x is the number
of emitted positrons from the VOI and a and b coefficients
to be determined from the fit. From the regression analysis,
it resulted b = − 0.54 ± 0.07 (with r2 = 0.86), indicating that
the homogeneity index is representative of image noise
(thereby associated with low counting statistics) and it is
likely to decrease in proportion to the square root of the
number of emitted positrons.
Absorbed dose calculations
The absorbed dose to the tumor cylindrical insert (Fig. 2k–o)
was calculated using different computational approaches,
namely: I) Full MC using Raydose II) Kernel-convolution
using Philips Stratos III) Local deposition (LD) algorithm IV)
MC N-Particle code (MCNP4c), assuming uniform activity
distribution V) MIRD analytical approach. Methods I–III use
90Y-PET images generated from the PET scanner for the
assessment of the absorbed dose at the voxel level. Therefore
differential dose volume histograms (dDVH) of the VOI
can be produced and compared. Methods IV–V allow
the average absorbed dose to the tumor insert to be deter-
mined assuming that the cylindrical insert is uniformly
filled with a known 90Y activity concentration. Therefore,
possible activity concentration non-uniformities are not
considered.
From a clinical point of view, microspheres become a
permanent implant. Therefore, dose calculations were
performed considering a single image (or activity con-
centration value) and assuming that the entire dose is
delivered over the 90Y physical half-life of 2.67 days.
A comparison of the calculated average absorbed dose
Fig. 2 Differential activity concentration volume histograms (dAVH). 90Y–PET images were reconstructed using a GE Discovery ST PET/CT system with
2.73 × 2.73 × 3.27mm3 detector elements. A full 3D-OSEM VUEPoint HD reconstruction algorithm, two iterations, 15 substeps, was used. Acquisitions at
day 1 and 4 were performed using 15 min scan time, while 30 min acquisition time was used for imaging at days 5, 6, and 12. Acquisition duration
was varied over time as we aimed to perform acquisition in realistic clinical conditions. Scan time below 30 min are very unlikely in the clinical practice
for activity concentrations below 2 MBq/mL, especially in the absence of a TOF scanner. Activity distributions of 90Y–PET images were analyzed in terms of
dAVHs. Positive skewness (indicated with s) was obtained for all dAVHs. a–e dAVH of the cylindrical insert fixed into the liver cavity of the anthropomorphic
phantom. Heterogeneous activity distributions were obtained for all acquisitions. f–j dAVH of the liver background. Visual inspection of the images (k–o)
showed the presence of hot and cold spots in the insert, supposed to be uniformly filled with 90Y. As a general rule, both for the tumor insert and the liver
compartment the lower the activity concentration, the higher the skewness value
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is shown in Fig. 5, where the different dose calculation
algorithms were applied to each of the clinical condition
reported in Fig. 2k–o. It is worth noticing that the possible
influence of the wall thickness is considered only in
Raydose and MCNP simulations. Raydose uses CT units to
determine attenuation coefficients for radiation transport;
therefore, perturbation effects of local heterogeneities
(e.g., PMMA phantom walls) are correctly accounted
for. Equivalently, a cylinder provided with a 1-mm thick
PMMA lateral wall (ρ = 1.19 g cm−3) was implemented in
MCNP simulations (elemental composition by weight:
H = 0.080538, C = 0.599848, and O = 0.319614). There-
fore, MC-based dose evaluations are reported with a
different pattern to differentiate MC calculations with
other algorithms that do not directly accounts for the
presence of the acrylic wall.
As a general rule, all dose algorithms provided com-
parable dose estimates with deviations within 9%, except
for dose calculations performed on day 1, where the
standard deviation over the average absorbed dose values is
20%. When compared to each other, LD, MIRD approach,
and Kernel-convolution methods provided comparable
absorbed doses with an average deviation within 6%
(maximum deviation 12% on day 1). Similarly, MC
codes provided comparable absorbed dose values to the
tumor insert, with an average deviation below 4%. Cal-
culations performed using kernel convolution algorithm
provided dose estimates in excellent agreement with
the well-known MIRD calculation method, with differences
below 5% for all acquisitions, except for day 12 where the
difference in the average absorbed dose is 17.7%.
Owing to the non-uniformity in the activity distribution,
the standard deviation of each dose point is generally large
(of the order of 30–40% of the dose value) and becomes
unacceptable when the activity concentration decreases
down to 0.22 MBq/mL (approximately 100% the dose
value). Figure 6 shows a comparison between dDVHs
generated by full MC calculations with Raydose, LD
algorithm, and convolution approach with Philips Stratos.
dDVHs were produced after a voxel-based dose estimation
of the cylindrical insert. In the present study, the DICOM
Structure Set format (RTSTRUCT) module was used to
Fig. 3 Anthropomorphic phantom used to validate the PET camera’s ability to produce 90Y quantitative data. The phantom is composed by a background
region (10,300 mL), a liver compartment (1200 mL), left (900 mL) and right lung (1100 mL), and a spine insert (200 mL). A homemade cylindrical PMMA
insert was manufactured and fixed into the liver cavity to simulate a hepatic lesion. The nominal volume of the insert is 19.13 mL (diameter 28.5 mm,
height 30 mm)
Table 2 Recovered activity in the tumor insert before and after compensation for partial volume effect through recovery
coefficients. Recovered activity concentrations are compared to measured values
Day of
scan
True activity
concentration
(MBq mL−1)
Average recovered concentration
(MBq mL−1) [1st–3rd quartile]
(no recovery coefficient applied)
Average recovered concentration
(MBq mL−1) [% deviation]
(recovery coefficient applied)
Homogeneity
Index
Reconstruction
parameters
Scan Time
(min)
1 5.50 ± 0.16 4.30 [3.24–5.36] 5.3 [− 3.6%] 0.34 2i, 15s 15
4 2.52 ± 0.08 1.95 [1.4–2.51] 2.41 [− 4.4%] 0.42 2i, 15s 15
5 1.94 ± 0.06 1.51 [1.12–1.88] 1.86 [− 4.1%] 0.36 2i, 15s 30
6 1.49 ± 0.04 1.03 [0.72–1.34] 1.27 [− 14.7%] 0.42 2i, 15s 30
12 0.31 ± 0.01 0.22 [0.076–0.294] 0.27 [− 12.4%] 1.01 2i, 15s 30
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transfer phantom structures and related data between the
workstations. Insert segmentation was performed so as to
exclude the PMMA wall from the contour. Results in Fig. 6
are presented in terms of dvi/dD, i.e., absolute volume
element (dvi) receiving dose in the corresponding dose
bin (dD). The integral under each differential DVH
yields the insert volume (nominal volume 19.13 mL).
VOI contouring performed using methods I and II pro-
vided a volume of 19.60 mL (+ 2.45%), while insert
contouring performed with Philips Stratos resulted in a
volume of 19.21 mL (+ 0.42%).
Absorbed dose measurement using LiF:Mg,Cu,P TLDs
Absorbed dose calculations presented in the previous
section were validated by absorbed dose to water measure-
ments using LiF:Mg,Cu,P chips inside a PMMA phantom
filled with a homogenous 90YCl3 aqueous solution. There-
fore, the average absorbed dose to water obtained from
TLD measurements was considered the gold standard
against which other dose algorithms can be benchmarked.
Each TLD had 4.5 mm diameter and was 0.8 mm height.
To this purpose, measurements were performed manufac-
turing six cylindrical phantoms the size of that used for
quantitative analysis (Fig. 7). Each cylindrical phantom
hosted a waterproof PMMA stick containing 3 TLD chips
encapsulated by a polystyrene envelope (for a total of 18
chips). The PMMA phantoms were manufactured so that
the radioactive liquid environment surrounds the whole
stick. The 60Co reference gamma beam available at ENEA-
INMRI was used to evaluate the calibration coefficient of
each TLD chip in terms of absorbed dose to water. Relative
standard uncertainty on the TLD calibration coefficient
was found to be in the range 0.7–2.2%.
The measurement of the absorbed dose from beta-
emitting radionuclides in liquid solution is not straight-
forward. The exclusion of radioactivity from the volume
occupied by the TLD is a major effect that needs to be
accounted for. Furthermore, the waterproof polystyrene
envelope unavoidably contributes to beta particle attenu-
ation during the measurement. Finally, as TLD calibration
was performed using a source and a geometry different from
the real experimental condition, an energy and geometry
correction factor needs to be considered. An accurate
description of the measurements equation is reported
in the “Methods” section, along with a detailed description
of correction and conversion factors.
Fig. 4 Quantitative analysis. a Recovered activity concentration in the tumor insert of the anthropomorphic phantom. Data are presented in
terms of minimum and maximum recovered activity values, 1st and 3rd quartile, average activity concentration and recovered activity concentration after
correcting for PVE. After the application of RCs, differences with measured activity concentration values reduce significantly with underestimations of the
order of 4% down to an activity concentration of about 2 MBq mL−1. b For each phantom acquisition HIdDVH were plotted as a function of the number
of positrons emitted from the VOI. A power function of the form y = axb was used to fit data points, where x is the number of emitted positrons from
the VOI and a and b coefficients to be determined from the fit. From the regression analysis it resulted b = − 0.54 ± 0.07 (with r2 = 0.86)
Table 3 Recovered activity in the liver background. Recovered activity concentrations are compared to measured values
Liver Background True activity concentration
(MBq mL−1)
Recovered concentration (MBq mL−1)
Average, [1st–3rd quartile] [% deviation]
Homogeneity
Index
Reconstruction
parameters
Scan Time
(min)
1 0.89 ± 0.03 0.76 [0.430–0.920] [− 14.6%] 0.84 2i, 15s 15
4 0.41 ± 0.01 0.37 [0.160–0.460][− 9.8%] 0.94 2i, 15s 15
5 0.31 ± 0.01 0.26 [0.140–0.330] [− 16.1%] 0.91 2i, 15s 30
6 0.24 ± 0.01 0.19 [0.090–0.240] [− 20.8%] 0.90 2i, 15s 30
12 0.051 ± 0.002 0.021 [0.004–0.030][− 58.8%] 2.80 2i, 15s 30
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PMMA samples were filled with 90YCl3 aqueous solution
with activity concentration of 6.7 MBq/mL, approximately.
Activity concentration was determined by measuring an
aliquot of the stock solution in terms of activity per unit
mass. Then, this was used to determine the activity of all
subsequent sources produced from this stock solution.
Accurate measurements of 90Y activity concentration were
performed using the ENEA-INMRI portable triple-to-
double coincidence ratio (TDCR) counter [40], with a
relative standard uncertainty below 1%. Measurement
time was 30 min approximately for each sample.
After measurement, each stick was removed from the
sample and TLD chips were manually removed from the
PMMA holder using dedicated tongs. One out of six
sticks holding the chips was wasted because of leaks in
the PMMA envelope that caused radioactive water to
get in contact with the chips. Furthermore, 8 TLD chips
were accidentally slightly contaminated during the removal
procedures. These data points were removed from the final
data as significantly higher.
The average absorbed dose to water per emitted beta par-
ticle was finally assessed as the weighted average of TLD
measurements and resulted to be (1.09 ± 0.07) × 10−11 Gy/
particle, with an associated relative weighted standard un-
certainty of 6.3%. The measured value can be compared
with the absorbed dose to water per emitted beta particle
obtained using two MC codes, namely MCNP4c and
Raydose.
With MCNP4c, the absorbed dose to water was calcu-
lated implementing the full cylindrical phantom geometry
into the code. A homogenous 90Y source was considered
into the phantom, and the delivered energy to water was
scored into geometrical cells the size of a TLD chip. Simu-
lations provided absorbed dose values per unit emitted
beta particle of (1.010 ± 0.005) × 10−11 Gy/particle.
On the other hand, image-based calculations with
Raydose were performed using the 90Y-PET acquisition
reported in Fig. 2k. Voxel-by-voxel absorbed dose calcula-
tions were performed on the cylindrical insert. Finally,
VOIs the size of a TLD chip (4.5 mm diameter, 0.8 mm
height) were drawn on the dose profile (Fig. 8). The average
absorbed dose per unit emitted beta particle was deter-
mined to be (1.06 ± 0.04) × 10−11 Gy/particle.
Overall, absorbed dose assessed with MC codes is in
excellent agreement with those obtained using TLD in
liquid solution, thus confirming the soundness of both
Fig. 5 Comparison of absorbed doses. Different dose calculation algorithms were used to compare average absorbed doses, namely (I) LD
algorithm (red), (II) MIRD analytical approach (violet), (II) Kernel convolution using Philips Stratos (blue), (IV) full MC using Raydose (green stripe
pattern), (V) MCNP4c (orange crosshatch pattern). The vertical bar chart displays the mean absorbed dose and its standard deviation. For methods
I-II-II, the standard deviation was assessed from dose-volume-histograms obtained after calculation. For methods IV and V, the activity of 90Y
contained in the cylindrical insert was recovered from 90Y–PET images using the dAVH approach described by Eq. 1. Then, the mean activity
value, along with its standard deviation, has been used to assess doses with methods IV and V, thus providing a mean dose ± standard deviation.
MC-based dose evaluations are reported with a different pattern to differentiate MC calculations with other algorithms that do not directly account for
the presence of the acrylic wall. Average absorbed doses are reported along with their standard deviations. All dose algorithms provided comparable
dose estimates with deviations below 9%, except for dose calculations performed on day 1, where the standard deviation over the
average absorbed dose values is 20%. Insert: comparison between average absorbed dose per unit activity into the cylindrical insert. When the
activity concentration decreases down to 0.22 MBq/mL (day 12) the standard deviation is approximately 100% the dose value
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calculation approaches (Table 4). This is especially true
for Raydose, which provided an absorbed dose value
within 3% of the measured dose, well within the stated
uncertainties.
Discussion
This study offers key insight into how different approaches
to dosimetry calculations can accurately assess the
absorbed dose after liver radioembolization using 90Y–PET
data. At a time of increasing evidence for an absorbed
radiation dose-effect relationships in radioembolization
with 90Y-laden microspheres [41, 42], it is the authors’ be-
lief that there is an urgent need for accurate dosimetry in
patients undergoing SIRT therapy. In fact, it is generally
accepted that the absorbed dose both to tumor areas and
to healthy liver is likely to have a significant impact on
treatment’s clinical effectiveness. Furthermore, since
microspheres administered during therapy remain trapped
within the microvasculature, imaging requirements reduce
to a single-time acquisition, thus simplifying the whole
Fig. 6 a–e Comparison of differential DVHs obtained in the cylindrical insert using the three voxel-based dose algorithms. (I) Full Monte Carlo calculations
with Raydose, (II) LD algorithm, and (III) convolution approach using Philips Stratos. Results are presented in terms of dvi/dD, i.e., absolute volume element
(dvi) receiving dose in the corresponding dose bin (dD). The integral under each differential DVH yields the insert volume (nominal volume 19.13 mL). VOI
contouring performed using methods I and II provided a volume of 19.60 mL (+ 2.45%), while insert contouring performed with Philips Stratos resulted in
a volume of 19.21 mL (+0.42%). The quantity Aavg represents the average insert activity concentration assessed from image-based evaluations. Real activity
concentrations, measured using the available dose calibrator, are reported in Table 2
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dosimetry process. As a consequence, there is great poten-
tial for SIRT dosimetry to become routine in the clinical
practice.
Patient-specific dosimetry in SIRT suffers from a number
of image-degrading effects. Besides PVE, that is likely to
play a major role in small lesions, low true coincidence
statistic due to the combined interplay of low beta plus
branching ratio and low achievable acquisition time are
likely to impact the image quality. Furthermore, the high
scatter component intrinsic of 90Y PET imaging may nega-
tively affect image quantification. Ultimately, patient re-
spiratory motion is the primary cause of image blurring
possibly leading to systematic dose underestimations [43].
In this study, we concerned ourselves with quantitative
accuracy of 90Y PET and the impact that different dose
calculation approaches have on image-based dosimetry
after liver radioembolization. Yet another question of
interest for us was to compare absorbed doses obtained
from MC calculations with those obtained through absorbed
dose measurements performed with TLD chips into a liquid
radioactive environment. To the best of our knowledge, this
line of research is the first to investigate the degree of
agreement between calculated and measured dose using
90Y–PET quantitative data.
Our data confirm and expand previous observations.
Since most scanner do not support 90Y as a viable radio-
nuclide option, scanner calibration should be performed
using surrogate radionuclides and applying proper decay
correction factors (e.g., 86Y [44, 45] or 22Na [46]). Quantita-
tive analysis showed that partial volume effects dominate
spheres of volume below 11.5 mL (diameter < 28 mm), ap-
proximately. Recovery of activity concentration measured
in the largest sphere on day 0 of imaging underestimated
the true activity concentration of − 15%, approximately.
Our results are in keeping with previous studies [18, 47].
However, the recent QUEST study [48] suggests that ToF-
PET scanners are likely to improve contrast of hot spheres
and increase RCs.
Another important consideration is that the low branch-
ing ratio for 90Y positron emission entails long scan times
in order to reduce image noise. This is especially true for
non-ToF–PET scanner, where the acquisition time plays a
key role. Quantitative analysis in anthropomorphic geom-
etry showed that despite the tumor insert being uniformly
filled with a homogenous 90YCl3 solution,
90Y–PET images
presented significant spatial non-uniformity. Notwithstand-
ing this, for activity concentrations exceeding 1.5 MBq/mL,
the recovered activity concentration underestimated the
known value by 4% approximately, demonstrating that
accurate quantitation of 90Y is possible if long scan time is
performed and if partial volume effects are accurately
compensated for. Quantitative accuracy decreases for
decreasing activity concentration levels. Interestingly, our
results are in close agreement with those obtained by Mille
et al. [49] which recovered 95.4% of the known activity in a
large cylindrical phantom despite obtaining noisy images
with a voxel variability of 21%.
Fig. 7 Technical drawing of the cylindrical phantom containing TLD chips surrounded by 90YCl3 aqueous solution. Custom PMMA cylindrical inserts
were manufactured at ENEA-INMRI to perform absorbed dose measurements with LiF:Mg,Cu,P thermoluminescence detectors
Fig. 8 Profile of the absorbed dose to water per emitted beta particle on
the cylinder axis, as calculated by Raydose. Voxel-by-voxel absorbed dose
calculations were performed using the acquisition in anthropomorphic
geometry reported in Fig. 2k. VOIs the size of a TLD (4.5 mm
diameter, 0.8 mm height) were drawn on the dose profile. The
average absorbed dose per unit emitted beta particle was determined
to be (1.06 ± 0.04) × 10−11 Gy/particle
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In the present study, the degree of uniformity was quanti-
fied in terms of homogeneity index. Quantitative data
demonstrated a noise-like behavior of the homogeneity
index, with the latter decreasing in proportion to the square
root of the number of emitted positrons. This finding sug-
gests that for the considered geometry and settings, image
non-uniformities are mainly imputable to the low-counting
statistics. It is interesting to note that activity underestima-
tion both in the tumor insert and in the liver compartment
is associated with increasing homogeneity index.
Of additional concern has been the impact of different
dose calculation algorithms in anthropomorphic geom-
etry. As a matter of fact, to date only a few studies
attempted to compare different dosimetry methods in
liver radioembolization. Mikell and co-workers [50] com-
pared four voxel-based dosimetry dose algorithms based
on 90Y bremsstrahlung SPECT images (namely, MC, soft-
tissue kernel with density correction (SKD), soft-tissue
kernel (SK), and LD method). Interestingly, the authors
found that for tumor, non-tumoral liver mean absorbed
doses calculated with SKD, SK, and LD are equivalent to
MC (within 5%). Deviations in the mean absorbed dose
values increase when dosimetry is performed in the lungs,
with right lung dosimetry being strongly influenced by the
liver–lung interface [50]. In another work, Grassi et al.
[51] compared STRATOS with a homemade software
package (VoxelMed), both in phantom and in patients
undergoing radiopeptide therapy with 177Lu. Both soft-
ware performed well, with an agreement within 5% in
phantom. Larger deviations were observed in patients.
In the present study, the large voxel variability of
absorbed dose values is related to the abovementioned
intrinsically noisy nature of 90Y PET images. However,
on average, absorbed doses to the tumor insert have
been found to be consistent to within 9%, except for
dose calculations performed on day 1, where the standard
deviation over the average absorbed dose values is 20%.
The most striking observation to emerge from the data
comparison is the difference between dose values obtained
with MC codes (namely, MCNP and Raydose) and other
algorithms. The foremost cause of the slightly lower dose
values obtained with Raydose is most probably due to the
resampling of the CT grid from 512 × 512 to 128 × 128,
executed for efficiency purposes. The larger voxel size,
together with the inhomogeneity in the underlying PET
images, produced a smoothing of the activity data. This is
evident in the fine distribution of the dose (Fig. 6a–e):
DVHs obtained with Raydose do not present any high-
dose tail as any hot spots in a single voxel are shared with
adjoining voxels. This is likely to produce lower doses
especially at the liquid–PMMA interface. On the other
hand, the lower doses obtained using MCNP could be
interpreted as being a result of: (i) the input activity
concentration, supposed to be uniformly distributed over
the entire cylindrical object and (ii) the absence of spill-in
activity from regions around the cylindrical insert in
MCNP simulations. This is likely to result in a lower dose
to the cylindrical insert.
Furthermore, when interpreting the results of the current
study, it is also important to note that the presence of the
PMMA wall of the cylindrical insert may had an impact on
dose calculations, possibly leading to biased estimates be-
tween methods that directly account for the acrylic edges
(Raydose, MCNP) and those that do not (kernel convolu-
tion, LD, and MIRD). The impact of the PMMA wall on
dose calculations is somehow expected and inevitable,
given the non-negligible presence of acrylic material
(4.98 g) if compared to the total mass of the insert when
filled with 90YCl3 (24.1 g). From a computational perspec-
tive, there is no substantial material difference between
tumor and background liver. As a consequence, this effect
is not expected in a clinical scenario, unless dose calcula-
tions are performed at the liver–lung interface, where dif-
ference in material density may play a key role [50].
Of note, average absorbed doses determined with the
LD method are in excellent agreement with those
obtained using the MIRD and the kernel convolution
dose calculation approach. This result provides a strong
argument for encouraging LD algorithm for the evalu-
ation of absorbed doses in the clinical practice, where
resource–intensive software packages are not always
available. Similar conclusions have been drawn in recent
research on the matter [26]. However, the large dose
variability at the voxel level—most likely due to a
scenario with low true coincidences and high random
fraction—raises questions about the possibility of using
dDVH for radiobiological modeling if acquisitions are
performed with a non-TOF scanner.
Table 4 Absorbed dose to water measured and calculated by MCNP4c and Raydose MC codes. D
meas
w and D
MCNP
w are in the ratio 1.08,
while D
meas
w and D
Raydose
w are in the ratio 1.03, well within the stated uncertainties. D
meas
w : absorbed dose per emitted beta particle measured
using LiF:Mg,Cu,P TLDs. DMCNPw : absorbed dose per emitted beta particle calculated using MCNP4c in analytical geometry. D
Raydose
w : absorbed
dose per emitted beta particle calculated running Raydose on 90Y–PET images
Average absorbed dose to water Relative weighted standard uncertainty (%)
Measurements, D
meas
w (1.09 ± 0.07) × 10
−11 Gy/particle 6.3
MCNP-4c, DMCNPw (1.010 ± 0.005) × 10
−11 Gy/particle 0.5
Raydose, DRaydosew (1.06 ± 0.04) × 10
−11 Gy/particle 3.8
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During the last 20 years, there has been increasing
interest in the measurement of absorbed doses from
internal beta emitters used in molecular radiotherapy. In
particular, TLDs have been extensively used in the past
to measure the absorbed dose both in phantoms [52]
and in animals [53–55]. However, to the best of the au-
thors’ knowledge, this is the first work that compares
absorbed doses obtained from 90Y–PET quantitative im-
aging procedures with those obtained from experimental
measurements using TL dosimeters. Direct Monte Carlo
radiation transport is presently considered to be the
most accurate of all currently available dose estimation
algorithms [56]. As a consequence, its validation using
dosimeters calibrated against absorbed dose primary
standards has become even more pressing. Our re-
search has confirmed the accuracy of MC calculations
in 90Y–PET dosimetry. Dmeasw and D
MCNP
w are in the ratio
1.088. This difference needs to be further investigated,
especially in the light of the well-known uncertainty of
MCNP cross sections at extremely low energies [57].
On the other hand, measured doses were in excellent
agreement with absorbed doses calculated using a full
MC approach, being Dmeasw and D
Raydose
w in the ratio 1.03,
well within the stated uncertainties.
The current research acknowledges a few limitations
that should be noted to aid interpretation of the result.
It is worth noting that the ability of a PET scanner to
perform accurate 90Y quantification relies on the know-
ledge of the internal pair production branching ratio.
Therefore, precise knowledge of the branch ratio of the
0+–0+ transition of 90Zr is important for an accurate
quantification of 90Y accumulated inside the target re-
gion and detected via PET acquisition. Most recent lit-
erature findings report an internal pair production
branch ratio as large as (3.186 ± 0.047) × 10−5 measured
by Selwyn [58] and colleagues using a HPGe detector.
This branch ratio value was used in the present study
for the absolute calibration of the PET system. It is desir-
able that in the near future, the current uncertainty on
the internal pair production branch ratio (about 1.5%)
will be reduced by more accurate experimental measure-
ments [59].
Furthermore, we focussed on absolute quantification
and dosimetry on a single cylindrical insert simulating a
liver lesion. The extent to which both our methods and
results can be generalized to other geometries and differ-
ent PET scanners certainly requires further investigation.
Finally, it is worth noticing that PET calibration mea-
surements should be repeated over a reasonable long
period of time to assess the system stability and to evalu-
ate the final uncertainty in the calibration factor. Unfor-
tunately, it was not possible in the present experiment
to investigate impact of repeated calibration measure-
ments due to the limited resources available.
Contrary to external beam radiotherapy, in which indi-
vidual patient dosimetry is mandatory and there are legal
requirements for accuracy (within 5% to a reference
point), there is a lack of standardization in molecular
radiotherapy (MRT), and it suffers from isolated efforts
to harmonize quantification and dosimetry approaches.
The current main source of uncertainty in internal dos-
imetry is in taking the step from dose measurements on
simple reference geometries to quantitative imaging mea-
surements of the complex and varying geometries of the
activity localized in real patients. This passage is essential
to comply with EC Directive 2013/59/EURATOM, Article
56, which states that individual dose planning for radiother-
apy patients (including MRT) must be enforced in legisla-
tion by EU member states by 6 February 2018. It is
desirable that in the near future, the final standard uncer-
tainty in absolute quantification in complex phantoms be
well below well 5% to ensure the uncertainty in clinical
absorbed dose estimations comply with the requirement of
5% to a reference point. Comprehensive guidance has yet
to be presented in this field, and there is no doubt that an
internationally endorsed protocol on 90Y PET/CT quantita-
tive imaging would lead to further advances in this area.
Conclusions
The results of this research are sufficient to conclude,
with some caveats, that patient-specific dosimetry is pos-
sible even in a scenario with low true coincidences and
high random fraction, as in 90Y PET imaging, granted that
accurate absolute PET calibration is performed and acqui-
sition times are sufficiently long. In the final analysis,
despite Monte Carlo calculations outperforming all dose
estimation algorithms, we believe to have gathered ample
evidence to recommend the use of the LD algorithm for
routine 90Y dosimetry based on PET/CT imaging, due to
its simplicity of implementation.
Methods
Uncertainty in activity measurements
Activity measurements required for the phantom study
were performed using the well-type radionuclide calibra-
tor available on site and traceable to the Italian National
Institute of Ionizing Radiation Metrology for the geom-
etry being measured (accuracy within ± 5% at k = 2 level,
as recommended by AAPM report 181). Weightings of
liquid solutions were performed with high-precision bal-
ances providing accuracies below 0.01%. Therefore, un-
certainties associated with volume measurements were
considered negligible.
Activity measurements needed for absorbed dose measure-
ments using LiF:Mg,Cu,P TL detectors in a liquid environ-
ment were performed using the ENEA-INMRI portable
triple-to-double coincidence ratio (TDCR) counter [35],
providing a relative standard uncertainty below 1%.
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PET scanner and reconstruction data
90Y PET images were acquired with a GE Discovery ST
PET/CT scanner (GE Healthcare, Milwaukee, WI, USA)
with lower energy threshold at 425 keV. Acquisition time
was 16 h for the reference phantom and 30 min per bed for
the anthropomorphic phantom. PET images were recon-
structed using the standard GE algorithm (full 3D-OSEM
VUEPoint HD two iterations, 15 subsets). PET coincidence
window is 12 ns, Peak NECR (3D) 38 kcps, energy reso-
lution 20%, and scatter fraction about 35%. PET scanner
sensitivity and spatial resolution were assessed in a previous
study [16]. PET data were corrected for attenuation, scatter,
random, and dead time using manufacturer software. Ran-
dom and scatter corrections are incorporated into the itera-
tive algorithm [60]. Scatter correction was performed using
a fully 3D approach that considers both the axial and trans-
axial scatter components, accurately modeling scatter from
hot regions in neighboring super slices and outside the scan
field-of-view resulting in greater quantitative accuracy (3D
model-based scatter correction, MBSC [61]).
Convolution algorithm
The convolution algorithm allows the absorbed dose
following 90Y microspheres administration to be calcu-
lated by the convolution of the 3D activity concentration
matrix A(x, y, z)with the 3D dose kernel for 90Y, K(x, y, z),
according to the following equation:
D x; y; zð Þ ¼ 1
λ
K x; y; zð Þ⊗A x; y; zð Þ½ 
¼ 1
λ
∭K x−x 0 ; y−y 0 ; z−z 0ð Þ⋅A x 0 ; y 0 ; z 0ð Þdx 0dy 0dz 0
⇒
discrete space 1
λ
X
x0
X
y0
X
z0
K x−x 0 ; y−y 0 ; z−z 0ð Þ⋅A x 0 ; y 0 ; z 0ð Þ½ 
ð3Þ
with λ ¼ ln 2ð ÞT1=2 decay constant of
90Y. Dose calculations
were performed using STRATOS, a voxel-based dose en-
gine on the IMALYTICS Research Workstation.
Local deposition algorithm
Local deposition algorithm has been recently proposed
for dose calculations whenever the energy released by
charged particles can be assumed to be locally absorbed
with in the same voxel as the decay. The other assumption
of local deposition algorithm is that the full width at half
maximum (FWHM) of the point spread function (PSF)
should be larger than the dose point kernel. This is be-
cause the output images can be regarded as a convolution
of the real object with the PSF of the system. In the ideal
case where PSF = Kernel, the imaging system simulates
the energy transport among voxels and the output image
can be regarded as the absorbed dose map.
The dose at a single voxel, Dvoxel, can be calculated as
the ratio of the energy delivered to the voxel, Evoxel, and
the mass of the voxel, mvoxel. Assuming a voxel density
ρ = 1 g cm3, mvoxel[g] = vvoxel[cm
3], with vvoxel voxel
volume. In the present study, images were reconstructed
using a voxel size as large as 0.273 cm×0.273 cm×0.327 cm.
Therefore, mvoxel = 0.024371 cm
3. The energy delivered to
the voxel can be calculated as the number of particles
totally emitted into the voxel (Ntot) times the average
energy delivered to the voxel by each particle (E):
Evoxel ¼ Ntot⋅E ð4Þ
Since microspheres are permanently implanted in the
patient with no removal from the region, the effective
half-life is simply the radioactive half-life and the num-
ber of 90Y particles totally emitted into the voxel can be
calculated as follows:
N tot ¼
Z∞
0
Avoxel0 exp −λtð Þ ¼ 1:44⋅Avoxel0 ⋅T 1=2 ð5Þ
With Avoxel0 initial activity into the voxel at t = 0, and
T1/2 half-life of the radionuclide. Regarding the average
energy delivered by each particle, E , the literature value
0.932 MeV can be assumed. Thus, the average energy
delivered to the voxel is:
Evoxel ¼ 1:44⋅Avoxel0 Bq½ ⋅T 1=2 s½ ⋅0:932 MeV½  ð6Þ
Avoxel0 is obtained from
90Y PET images. In fact, as
90Y–PET images are calibrated in terms of activity
concentration, Cvoxel, (i.e., each voxel—i is expressed in
term of Bq mL−1) the activity into the voxel is given by:
Avoxel ¼ Cvoxel BqmL
 
⋅vvoxel mL½  ð7Þ
Thus, the dose at a single voxel, Dvoxel, can be calcu-
lated as follows:
Dvoxel
¼ 1:44⋅Cvoxel BqmL
 
⋅vvoxel mL½ ⋅T1=2 s½ ⋅E MeV½ ⋅1:602⋅10−13 JMeV
 
mvoxel kg½ 
ð8Þ
Dvoxel Gy½  ¼ Cvoxel BqmL
 
⋅4:966⋅10−5 Gy⋅s⋅mL½  ð9Þ
Absorbed dose measurement equation for TLD dosimetry
In the considered experimental geometry the absorbed
dose to water was determined from the TLD reading
through the following equation:
Dw ¼ TL E90Yð Þ⋅N60CoDw ⋅kfv⋅H
exp;ref
90Y ;60Co ⋅kmat ð10Þ
where
 TL E90Yð Þ is the TLD reading after irradiation with
90Y beta particles during measurement.
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 N 60CoDw ¼
Dw 60Coð Þ
TL 60Coð Þ is the TLD calibration coefficient at
60Co quality, with Dw(
60Co) absorbed dose to water
delivered to the TLD and TL(60Co) the TLD reading
after irradiation.
 kfv, finite volume effect, is the loss of absorbed dose
due to exclusion of radioactivity from the volume
occupied by the TLD.
 H 90Y; 60Co
exp;ref ¼ D
90Y
w =D
90Y
TLDð Þ exp geom
D60Cow =D
60Co
TLDð Þref geom is the energy and
geometry correction factor, given by the ratio of
absorbed doses to water and to TLD material at different
radiation qualities and different irradiation geometries.
This is calculated by the ratios of Dw/DTLD (TLD to
water conversion factor), taking into account differences
between measurement conditions (exp_geom) and
reference calibration conditions (ref_geom).
 kmat, correction factor due to the presence of
materials other than TLDs, i.e., PMMA stick hosting
the three TLDs and the waterproof PMMA envelope
surrounding the stick.
All correction factors reported in Eq. 3 were determined
using Monte Carlo simulations with MCNP4c code.
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